Evidence map›Paper›PMID 39692835›Full record

ArticleInternational journal of clinical oncology2025

Efficacy of androgen receptor signaling inhibitors in combination with androgen deprivation therapy for castration-sensitive metastatic prostate cancer: a retrospective analysis in a Japanese cohort.

Minekatsu Taga, Takeshi Sasaki, Shinichiro Higashi, Shoichi Kimura, Atsuro Sawada, Katsuki Tsuchiyama, Takahiro Inoue, Toshiyuki Kamoto, Naoki Terada

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Minekatsu TagaDepartment of Urology, Faculty of Medical Science, University of Fukui, 23-3 Matsuoka-shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.
Takeshi SasakiDepartment of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan.
Shinichiro HigashiDepartment of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan.
Shoichi KimuraDepartment of Urology, University of Miyazaki, Miyazaki, Japan.
Atsuro SawadaDepartment of Urology, University of Miyazaki, Miyazaki, Japan.
Katsuki TsuchiyamaDepartment of Urology, Faculty of Medical Science, University of Fukui, 23-3 Matsuoka-shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan.
Takahiro InoueDepartment of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan.
Toshiyuki KamotoDepartment of Urology, University of Miyazaki, Miyazaki, Japan.
Naoki TeradaDepartment of Urology, Faculty of Medical Science, University of Fukui, 23-3 Matsuoka-shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui, 910-1193, Japan. nterada@u-fukui.ac.jp.ORCID http://orcid.org/0009-0005-1082-6089

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to evaluate the efficacy of androgen receptor signaling inhibitors (ARSIs) combined with androgen deprivation therapy (ADT) for treating castration-sensitive metastatic prostate cancer in Japanese patients, focusing on the effects on time to the development of castration-resistant prostate cancer (CRPC) and overall survival (OS).

methodsThis retrospective muti-institutional analysis included 332 patients diagnosed with metastatic prostate cancer in Japan between 2018 and 2023. The patients were categorized into two groups: patients receiving ADT combined with ARSI (ARSI group) and those receiving ADT alone or with bicalutamide (ADT group). Data on demographics, treatments, and outcomes were compared using the Kaplan-Meier method with propensity score matching.

resultsWe found an increasing trend in ARSI use over time. The median time to CRPC was significantly longer in the ARSI group than in the ADT group (47.1 vs. 15.2 months, p < 0.001); however, no significant differences in OS were observed before or after propensity score matching. The 1-year-survival rate of patients in the ARSI group tended to be higher than that of patients in the ADT group in subgroups with high tumor volume (96.1% vs. 85.0%) and high Gleason grade (98.1% vs. 85.9%).

conclusionsAdding ARSI to ADT extended the time to CRPC but did not significantly affect OS. However, it potentially suppressed the short-term risk of death in high-risk subgroups. This study highlights the need for further research to explore the characteristics of Japanese patients with metastatic prostate cancer in whom upfront ARSIs are effective.

Indexed as

Androgen AntagonistsAndrogen Receptor AntagonistsAntineoplastic Combined Chemotherapy ProtocolsProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overAnilidesEast Asian PeopleHumansJapanMaleMiddle AgedNeoplasm MetastasisNitrilesReceptors, AndrogenRetrospective StudiesAndrogen AntagonistsAndrogen Receptor AntagonistsAnilidesAR protein, humanbicalutamideNitrilesReceptors, AndrogenTosyl CompoundsAndrogen deprivation therapyAndrogen receptor signaling inhibitorCastration-resistant prostate cancerMetastatic prostate cancerOverall survival

Identifiers

PMID39692835
PMCPMC11785660

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.